Trade Alert: The Chief Business Officer Of Cellectar Biosciences, Inc. (NASDAQ:CLRB), Jarrod Longcor, Has Just Spent US$75k Buying 893% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the Cellectar Biosciences, Inc. (NASDAQ:CLRB) Chief Business Officer,
Jarrod Longcor, recently bought US$75k worth of stock, for US$1.15 per share. While that isn't the hugest buy, it actually boosted their shareholding by 893%, which is good to see.
Check out our latest analysis for Cellectar Biosciences
Cellectar Biosciences Insider Transactions Over The Last Year
Notably, that recent purchase by Jarrod Longcor is the biggest insider purchase of Cellectar Biosciences shares that we've seen in the last year.
So it's clear an insider wanted to buy, at around the current price, which is US$1.18. Of course they may have changed their mind. But this suggests they are optimistic. If someone buys shares at well below current prices, it's a good sign on balance,
but keep in mind they may no longer see value. Happily, the Cellectar Biosciences insiders decided to buy shares at close to current prices.
In the last twelve months Cellectar Biosciences insiders were buying shares, but not selling. You can see a visual depiction of insider transactions
(by individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Insider Ownership of Cellectar Biosciences
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. Our information indicates that Cellectar Biosciences insiders own about US$35k worth of shares. We might be missing something but that seems like very low insider ownership.
What Might The Insider Transactions At Cellectar Biosciences Tell Us?
It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence.
But on the other hand, the company made a loss during the last year, which
makes us a little cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership;
their transactions suggest that they are quite positive on Cellectar Biosciences stock. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision.
At Simply Wall St, we've found that Cellectar Biosciences has 5 warning signs (2 don't sit too well with us!) that deserve your attention before going any further with your analysis.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Love or hate this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives,
your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Thank you for reading.
, Jarrod Longcor, Has Just Spent US$75k Buying …){kind=link}